Myriad Weighs Strategic Alternatives
This article was originally published in The Pink Sheet Daily
Executive Summary
Management is undertaking a strategic review to evaluate alternatives for running its diagnostics and pharmaceuticals business separately.
You may also be interested in...
ACOG Guideline Revisions Boost Myriad’s BRCA Test
Pharma-like direct-to-consumer ads should help boost diagnostic’s sales, and AstraZeneca trials could establish use with PARP inhibitors.
ACOG Guideline Revisions Boost Myriad’s BRCA Test
Pharma-like direct-to-consumer ads should help boost diagnostic’s sales, and AstraZeneca trials could establish use with PARP inhibitors.
Newly Independent Myriad Diagnostics Will Pursue Product Acquisitions
Pharmaceutical group to proceed as an independent developer of cancer, infectious disease therapies.